67915-31-5
67915-31-5 結(jié)構(gòu)式
基本信息
曲康唑
特康唑
TERCONAZOLE
Terconagole
TERCONAZOLE EPT(CRM STANDARD)
TERCONAZOLE USP(CRM STANDARD)
Triaconazole
1-[4-[[(2R,4S)-2-(2,4-Dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-yl-piperazine
Fungistat
Piperazine, 1-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, cis
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
常見(jiàn)問(wèn)題列表
曲康唑?qū)δ钪榫?、許表皮癬菌和其他真菌有抗菌作用對(duì)某些細(xì)菌也有抗菌作用；主要用于外陰陰道念珠菌病的治療。
對(duì)0.4%曲康唑和2%咪康唑膏的不良反應(yīng)進(jìn)行研究，曲康唑組皮疹、生殖道刺激、疼痛和妁熱的發(fā)生率分別為1.3%、3.1%、1.2%和5.2%；咪康唑組生殖道刺激、疼痛和妁熱的發(fā)生率分別為0.9%、3.1%、10.5%，咪康唑組患者未出現(xiàn)皮疹，有2%患者出現(xiàn)流涕(rhinorrhea)。比較曲康唑陰道栓80mg和咪康唑栓的不良反應(yīng)情況，分別有6.3%的曲康唑組患者和0.7%咪康唑組患者用藥后出現(xiàn)腹痛，兩組患者的其他不良反應(yīng)發(fā)生率相似。Hyder等(1994)報(bào)道應(yīng)用曲康唑治療VVC后患者出現(xiàn)發(fā)熱和白細(xì)胞升高。
Terconazole inhibits the growth of Candida albicans ATCC 44859 in a concentration-related manner, but with modest effects noted at levels from 0.1 to 10 μM when the yeast is grown on media favoring the cell form. The inhibitory potency of terconazole on yeast cell viability varies with the strain and species of Candida tested. The susceptibility of C. albicans ATCC 44859 to terconazole is markedly enhanced when the yeast is grown on Eagle minimum essential medium, which favors mycelium formation. There is a progression of changes, from loss of mycelia formation at 0.1 μM terconazole through complete necrosis at 100 μM. Terconazole blocks the morphogenetic transformation from the yeast into the filamentous form at concentrations of 0.008 to 0.05 microgram/mL.
A 3-day once-daily intravaginal application of terconazole 0.8% is usually sufficient to provide a functional therapeutic period of 7 days because of prolonged high biologically active antifungal levels in the vagina. No side effects are observed at any concentration of terconazole.